Blockade of the renin-angiotensin system: Better late than never

American Journal of Kidney Diseases

Volumn 43, Issue 6, 2004, Pages 1113-1115

  Thomas, Merlin C ^a   Cooper, Mark E ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LACIDIPINE; LOSARTAN; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETIC NEPHROPATHY; DRUG MECHANISM; EDITORIAL; GLOMERULUS FILTRATION RATE; HORMONE ACTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOVOLEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; NONHUMAN; PATIENT MONITORING; PERIOPERATIVE PERIOD; PHARMACOLOGICAL BLOCKING; POSTOPERATIVE CARE; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; RISK ASSESSMENT;

EID: 2542453926     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2004.03.038     Document Type: Editorial

References (14)

1. Sadoshima J: Cytokine actions of angiotensin II. Circ Res 86:1187-1189, 2000
2. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H: Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 43:1056-1064, 2004
3. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC: Effects of an angiotensin converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 139:105-112, 2003
4. Diaz-Buxo JA, Lowrie EG, Lew NL, Zhang SM, Zhu X, Lazarus JM: Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am J Kidney Dis 33:523-534, 1999
5. Huland H, Bause HW, Clausen C, Doehn N: The influence of an angiotensin II antagonist, saralasin, given before donor nephrectomy, on kidney function after transplantation. A controlled prospective study. Transplantation 36:139-142, 1983
6. Thomas MC, Mathew TH, Russ GR, Rao MM, Moran J: Perioperative blood pressure control, delayed graft function, and acute rejection after renal transplantation. Transplantation 75:1989-1995, 2003
7. Chien S, Li S, Shyy YJ: Effects of mechanical forces on signal transduction and gene expression in endothelial cells. Hypertension 31:162-169, 1998
8. Cerwinka WH, Granger DN: Influence of hypercholesterolemia and hypertension on ischemia-reperfusion induced P-selectin expression. Atherosclerosis 154:337-344, 2001
9. Frei U, Schindler R, Wieters D, Grouven U, Brunkhorst R, Koch KM: Pre-transplant hypertension: A major risk factor for chronic progressive renal allograft dysfunction? Nephrol Dial Transplant 10:1206-1211, 1995
10. Cosio FG, Pelletier RP, Pesavento TE, et al: Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. Kidney Int 59:1158-1164, 2001
11. Palmer BF, Dawidson I, Sagalowsky A, Sandor Z, Lu CY: Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 52:640-645, 1991
12. Lorenz M, Billensteiner E, Bodingbauer M, Oberbauer R, Hörl WH, Haas M: The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function. Am J Kidney Dis 43:1065-1070, 2004
13. Amuchastegui SC, Azzollini N, Mister M, Pezzotta A, Perico N, Remuzzi G: Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 9:1948-1955, 1998
14. Shahinfar S, Dickson TZ, Ahmed T, et al, for the RENAAL investigators: Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study. Kidney Int Suppl 82:64-67, 2002